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The production of antibodies after immunization requires antigen recognition
by B cells, expansion ofthe pool of antigen-reactive B cells, and finally, differentia-
tion of these B cells into antibody-secreting plasma cells . Current models for this
process of B cell maturation in humans involve separate signals for B cell activation,
proliferation, and differentiation (1, 2) . One ofthe lymphokines that has been shown
to enhance B cell proliferation is a 50-60-kD product of activated T cells and of
the Namalwa cell line termed high molecular weight B cell growth factor (HMW
BCGF)t (3). Human HMWBCGF has been purified to homogeneity, and this mol-
ecule has no obvious analog among the B cell growth factors of mice .
The environment of an ongoing immune response often includes the activated
products of various inflammatory cascades, such as clotting or complement proteins .
Multiple complement activation fragments have been shown to modulate the im-
mune response, including C3a, C5a, C3b, C3d, and Ba (4-9) . Engagement of B
cell receptors for C3b (CRI) and C3d (CR2) by antibodies can also influence B cell
proliferation (10, 11) . The possibility that Bb can affect immune responses in vitro
has been suggested (12) but has not been systematically investigated . In the present
work, we have studied the modulatory influence of the complement activation frag-
ment Bb on B lymphocyte function in detail . We have shown that Bb can induce
activated but not unactivated B cells to proliferate and can act synergistically with
IL-2 and B cell differentiation factors to induce B cell differentiation into antibody-
secreting cells. This effect is mediated by direct interaction with B cells rather than
by any effect of Bb on macrophage function (13). Interestingly, Bb has antigenic
homology to HMW-BCGF, and its effects on B cell function are quite similar to
those ofHMW-BCGF. Moreover, Bb and HMW-BCGF compete for binding to the
B cell plasma membrane . From these data we conclude that the Bb activation frag-
ment of complement Factor B has a stimulatory effect on the proliferation of acti-
vated human B cells via a mechanism similar to HMWBCGF, and that Bb may
bind to the HMWBCGF receptor on activated B cells . These data imply that at
sites of inflammation, Bb may mimic the effects of this proliferative lymphokine .
This work was supported in part by National Institutes of Health grant GM-38330 (E . Brown) . Address
correspondence to Marion Peters, Washington University School of Medicine, Box 8124, 660 South
Euclid Ave ., St . Louis, MO 63110 .
' Abbreviations used in this paper: CM, complete medium; HMW-BCGF, high molecular weight B cell
growth factor; NPGB, paranitrophenyl paraquanidinobenzoate ; SAC, Staphylococcus aureus Cowan I .
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Bb STIMULATES B CELL PROLIFERATION
Thus, Bb may be a very early specific proliferative signal for B cells, to be followed
after ingress and activation of T cells by the HMW-BCGF signal itself. This sug-
gests a novel mechanism by which products of inflammatory reactions may influence
the immune response .
Materials and Methods
Materials . Materials used were PHA (2 pg/ml ; Wellcome Diagnostics, Beckenham, UK);
IL-2 (2 IU/ml ; Cellular Products Inc., Buffalo, NY) ; Staphylococcus aureus Cowan-I (SAC;
1 :25,000, vol/vol ; American Type Culture Collection, Rockville, MD); mixed lymphocyte
culture supernatants ; and polyclonal anti-Factor B antibody (Cytotech, San Diego, CA) . HMW-
BCGF was the purified product of PHA-stimulated Namalwa cells (3) . Mixed lymphocyte
culture supernatant has been shown to contain both IL-2 and B cell differentiation factor
activity (14) . BCGF1C2 is an mAb that recognizes HMW-BCGF (3) . P3X is a mouse IgGI
control mAb with no known specificity.
Complement Component Purification . C3, C3b, Factor B, and Factor D were purified as pre-
viously described (15-18) . For some Western blots, commercially available Factor B was used
(Cytotech) . Ba and Bb were prepared by incubating C3b at 1 .5 mg/ml with Factor B (10 mg/ml)
and Factor D (10 pg/ml) for 1 h at 37°C (19) . The Bb and Ba were repurified by DEAE-
Sephacel chromatography (13) followed by chromatography on ACA-54 and anti-C3-Sepharose.
In some cases the Ba and Bb each were further purified by TSK-3,000 gel permeation chro-
matography. Under these conditions the Bb and the Ba exhibit single homogenous peaks
by SDS-PAGE . For some experiments the Bb was treated with an irreversible serine protease
inhibitor, paranitrophenyl paraguanidinobenzoate (NPGB), for 30 min at room tempera-
ture. Excess NPGB was removed by extensive dialysis with saline before use . Bb so treated
lost enzymatic activity as assessed by hydrolysis ofN-acetyl-glycl-lysyl-methyl ester (20), as-
sayed as described (21) .
Cell Purification. Human mononuclear cells were purified from heparinzed peripheral blood
by Ficoll-Hypaque (Pharmacia Fine Chemicals, Piscataway, NJ) gradient centrifugation (22) .
Human tonsils and spleens were purified by dispersing tissue through mesh into single cell
suspensions and mononuclear cells obtained by Ficoll-Hypaque . B and T cells were obtained
from mononuclear cells by monocyte depletion (glass bead adherence and G-10 columns)
followed by rosetting with 2-aminoethylthiouronium bromide-treated sheep RBC (23-25) .
B cells were 80-95% surface Ig positive and <2% "E" rosette positive . T cells were >95 0/0
"E" rosette positive . In all assays, the incorporation of [ 3H]TdR in response to PHA was as-
sessed to ensure the functional purity ofthe B cells . In some experiments, B cells were further
separated by size into small, medium, and large populations using counter-current elutria-
tion as described (26) . Monocytes were obtained by adherence or counter-current elutriation
(26) . The MB cell line is an EBVtransformed cell line from a normal individual, cultured
and maintained as described (27) .
Cell Proliferation . 105 cells were cultured in 0.2 ml complete medium (CM ; 10% heat-
inactivated FCS in RPMI 1640 with 50 pg/ml gentamicin) in the presence of SAC and var-
ious cytokines . Proliferation was measured by [ 3H]TdR incorporation over the last 18 h of
a 96-h culture . In some experiments, 10 5 monocytes were cultured in 1 ml CM for 4 and
24 h with and without Bb (10 wg/ml ; 170 nM) and the supernatants were obtained . 104 mono-
cytes were also incubated overnight with Bb at 10 pg/ml (170 nM) . The monocytes were then
washed and placed in culture with 10 5 SAC-activated B cells in 0.2 ml CM.
Western Blot Analysis . Analysis was performed as described (3), using transfer to Immobilon
paper (Millipore Continental Water Systems, Bedford, MA). SDS-PAGE was performed
without reduction on 10% acrylamide gels .
Ligand Binding Experiments . Bb was labeled with Na 1251 using chloroglycoluril (28) . Var-
ious preparations had specific activities ranging from 2 .5 to 5.3 ACi/nmol . For binding curves
and Scatchard plots, 10 6 B cells, or MB cells, with or without 6 AM (360 pg/ml) unlabeled
ligand, were incubated with various concentrations of 1251-Bb at 4°C for 2 h . Bound and
free ligand were separated by centrifugation of the reaction mixture through 250 pl Versi-
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lube F-50 (General Electric Co ., New York, NY) at 12,500 g, following which, the cell pellet
(bound ligand) and the supernatant (free ligand) were counted separately in agamma counter.
Specific binding was calculated as binding in tubes without excess cold Bb minus binding
in tubes containing excess cold Bb. Under these conditions nonspecific binding represented
0.22 ± 0.01% of input cpm. All determinations were performed in duplicate.
Results
Effect ofBb on B Cell Function . Because of the possibility that Bb could affect im-
mune responses (12), we systemtically examined the effect of Factor B and its larger
cleavage fragment, Bb, on cellular immune function . Preliminary data suggested
that Bb did not influence T cell proliferation in response to PHA. Bb also did not
influence activation of purified resting B cells . In the absence of activation of the
B cells by SAC, Bb had little effect on subsequent proliferation (Fig . 1) . However,
after the B cells had been activated with SAC, Bb markedly enhanced proliferation
in a dose-dependent manner (Figs. 1 and 2 A) . On the other hand, intact Factor
B hadno effect on the proliferation ofunactivated or activated B cells (data not shown) .
Bb also enhanced B cell proliferation in the presence of suboptimal HMW-BCGF
concentrations in a dose-dependent manner (Fig . 2 B) . However, maximal prolifer-
ation in the presence of HMW-BCGF and Bb was no greater than in the presence
of Bb alone (compare Fig. 2 A and B) or in the presence of optimal HMW-BCGF
alone (data not shown), suggesting that the effects of HMW-BCGF and Bb were
additive, and not synergistic. Since Bb enhanced only the proliferation of B cells
that had been activated in vitro by SAC, we tested the effect of Bb on proliferation
of in vivo preactivated B cells . These cells, which presumably have been stimulated
by antigen in vivo, are large and can be isolated from smaller unstimulated B cells
by counter-current elutriation (26) . As shown in Fig. 3, Bb markedly enhanced prolifer-
ation of these larger activated B cells at concentrations >1 gg/ml (N17 nM), while
its effect on smallerB cells was far less marked . Thus, the larger preactivated B cells
are more susceptible to the effect of Bb. These data suggested a functional similarity
between Bb and HMW-BCGF Like Bb, HMW-BCGF enhances proliferation of
SAC-stimulated, or in vivo preactivated B cells, but has little effect on small unacti-
vated B cells (29) . In addition, Bb had no effect on Ig production when added alone
or with SAC, which is also similar to HMW-BCGF (29) . This, and the fact that
Bb could not further enhance proliferation of B cells optimally stimulated with HMW
FIGURE 1 . Bb enhanced the proliferation ofSAC-stimulated
B cells but had no significant effect on its own. ['HIT in-
corporation by B cells activated by SAC, PHA (2 1Ig/ml),
and Bb (1 gg/ml) . Mean t SD of three experiments .
1228
	
Bb STIMULATES B CELL PROLIFERATION
ua o to° to' toe toe to " unat o i& to' toz toe to'
Bb added (ng/ml) Bb added (ng/ml)
B FIGURE 2 . Bb enhanced the proliferation of
SAC-stimulated B cells alone (A) and in the pres-
ence of suboptimal concentrations of HMW
BCGF. (A) Mean t SD of [ 3H]T incorporation
by unstimulated B cells (unst) and B cells stimu-
lated with SAC and Bb (1-10,000 ng/ml) . (B)
Mean t SD of [3H]T incorporation by un-
stimulated and B cells stimulated with SAC, 1070
HMW-BCGF, and varying concentrations of Bb.
The proliferative effect of Bb was dose respon-
sive over this range.
BCGF suggested that the two proliferative stimuli mightbe acting through a similar
mechanism.
This hypothesis suggested that the effect of Bb wasdirectly on B cells rather than
on monocytes, a previously described target of Bb action (13) . To test whether Bb
acted indirectly on B cell proliferation via modulation of monocyte function, we
performed two experiments. In one, monocytes were cultured for 4 and 24 h in the
presence or absence of 10 wg/ml (170 nM) of Bb . Supernatants were harvested and
then placed in culture with SAC-activated B cells. Monocyte supernatants with or
without Bb stimulated SAC-activated B cell proliferation; thus, the effect of Bb could
not be evaluated under these conditions . Therefore, we performed a second series
of experiments in which monocytes were cultured overnight in the presence of Bb
at 10 wg/ml (170 nM). After this preincubation the cells were washed and placed
in culture with SAC-activated B cells. Preincubation of monocytes with and without
Bb had similar effects on subsequent B cell [3H]Tdr incorporation (1,884 ± 227 and
1,331 ± 169 cpm, respectively), which was above unstimulated cultures (293 t 65)
but less than optimally stimulated cultures (26,876 ± 1,633 cpm) . Thus, Bb did
not enhance monocytes' ability to affect B cell proliferation.
Next, we evaluated the effect ofthe serine protease inhibitor NPGB on B cell prolifer-
ation induced by Bb . Because Bb's effect on macrophage spreading requires preser-
vation of its serum esterase activity (21), we examined whether this was true for its
enhancement of B cell proliferation. If the proteolytic activity of Bb were required,
it might also be true that HMW-BCGF enhances proliferation via a protease ac-
80
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FIGURE 3 . Bb enhanced the proliferation of larger in vivo activated B
cells (0) more than smaller resting B cells (A). B cells were separated
by size and stimulated with SAC and 1070 HMW-BCGF. Bb was added
as indicated. The ordinate shows the mean percent increase in ['HIT
incorporation of triplicate samples compared with the absence of Bb .
tivity. However, as shown in Table I, neither the proliferative effect of Bb nor of
HMW-BCGF was diminished by treatment with NPGB. Thus, the mechanism of
enhancement of B cell proliferation by Bb is quite distinct from its effects on macro-
phage spreading. These data present additional evidence that the effect of Bb on
B cell proliferation is not mediated via an indirect activation of a few contaminating
macrophages in the B cell preparations .
Bb Binds to BLymphocytes.
	
Thehypothesis that Bb acts directly on B cells to effect
proliferation suggests that there is a binding site for Bb on B cells . We examined
the binding of 1251-Bb to SAC-stimulated tonsillar B cells and to the MB cell line .
1251-Bb bound saturably to preparations of activated tonsillar B cells, as demon-
strated by the ability of unlabeled ligand to inhibit the binding of the radiolabel
(Fig . 4A) . Remarkably, HMW-BCGF also inhibited the binding of 1251_Bb to acti-
vated B cells, suggesting that Bb and HMW-BCGF bound to the same receptor on
these cells. The unrelated molecules IgG and Ba did not affect the binding of 125I_
Bb. To ensure that this binding was to B cells rather than to contaminating macro-
phages, we also examined the binding of 1251-Bb to the EBVtransformed B cell line,
MB (Fig . 4 B). MB exhibits many of the surface characteristics of activated B cells,
including expression of the receptor for HMWBCGF (27) . MB also bound Bb
specifically, and as with activated untransformed B cells, this binding was inhibited
c
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TABLE I
Serine Protease Inhibitor NPGB Does not Inhibit Bb or
HMW-BCGF-stimulated Proliferation of SAC-activated B Cells
Bb was treated with NPGB or buffer, dialyzed, and then added to SAC-stim-
ulated B cells .
: Mean t SD of triplicate determinations .
25,000
i
0.25 0.5 0.75 I +cold Bb +cold
pM Cold Ligond (IPM) HMMC
GF
25 50 100
pl Cold HMW-BCGF
5,000N
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FIGURE 4 . Bb binding to B cells
and an EBVtransformed B cell
line . 121 1-Bb at 30 ag/ml (500 nM)
was incubated with 106 SAC-acti-
vated tonsillar B lymphocytes (A)
or with 2 x 10 6 MB cells (B) as de-
scribed in Materialsand Methods .
Both unlabeled Bb and unlabeled
HMW-BCGF inhibited binding of
12'1-Bb to these cells. Neither IgG
(A) nor Ba (data not shown) in-
hibited 121 1-Bb binding .
SAC plus : Buffer'
[3H]TdR incorporation
NPGB"
CPm
- 22,989 t 3,931 : _
Bb (1 vg/ml) 56,226 ± 4,366 50,888 t 3,145
10 01o BCGF 48,204 f 1,950 50,501 ± 2,101
10% BCGF + Bb (1 gg/ml) 79,526 t 6,936 66,350 t 10,352
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by cold HMW-BCGF. Scatchard analysis of the saturable binding of Bb to SAC-
activated normal B cells and MB cells was performed. As shown in Fig. 5, Bb bound
to activated normal B cells with a Kd of 110 ± 19 nM (6.6 gg/ml) and there were
21,000 ± 3,500 sites per cell (mean ± SEM, n = 3) . Analysis of binding to MB
cells showed a sightly lower affinity (Kd: 152 ± 19 nM: 9 ug/ml) with more binding
sites per cell (54,000 t 8,000, mean ± SEM, n = 4) . Together these data demon-
strate that there is a Bb receptor on the activated B cells themselves, and that the
Bb receptor is closely related or identical to the B cell receptor for HMW-BCGF.
Factor Band Bb Are Antigenically Related to HMW-BCGF Because of the similarity
in functional effect ofBb and HMW-BCGF, as well as their similar molecular weights
and apparent crossinhibition of binding to B cells, we examined the two molecules
for antigenic homology. We first probed with BCGFIC2, an mAb to HMW-BCGF,
which inhibits its function (3) . As shown in Fig. 6, BCGFIC2 bound to both Bb
(lane 3) and Factor B (lane 5), as well as HMW-BCGF (lane 1) . BCGFIC2 did not
recognize Ba (lane 4) or proteins in 10% FCS (lane 2) . BCGFIC2 bound to both
Factor B made in our laboratory and to commercially prepared Factor B, both of
which showed a single band on SDS-PAGE. The binding to Factor B was quite specific,
since it was the only protein recognized by BCGF-1C2 when a 12-30% PEG fraction
of normal human plasma was subjected to electrophoresis and then analyzed by
Western blot analysis (data not shown) . Using a polyclonal anti-Factor B antibody,
we performed reciprocal experiments to look for binding ofthis antibody to HMW-
BCGF. As shown in Fig. 7, the polyclonal anti-Factor B recognized HMW-BCGF
(lanes 1 and 2) as well as Bb (lane 3), and Ba (lane 4) . The Coomassie stains of
the FB preparations used are shown in Fig. 7 B with Ba in lane 1 ; Bb in lane 2;
and FG in lane 3. These experiments with antibodies to both Factor B and HMW-
BCGF demonstrated antigenic homology between Factor B and HMW-BCGF. Of
particular interest was the finding that BDGFIC2, which inhibits the function of
HMW-BCGF, crossreacted with Bb. This suggested that the close functional ho-
mology between the two molecules might be mediated via structurally similar do-
mains that reacted with the B cell plasma membrane .
Monoclonal anti-HMW-BCGFInhibits the Proliferative Signal ofBb. The data obtained
in the preceding studies suggested that Bb and HMW-BCGF might be homologous
in a domain recognized by aB cell receptor important in signalling cellular prolifer-
ation . To test this directly, we used the mAb BCGFIC2, which inhibits HMWBCGF
action on B cells (3), andwhich binds to Bb (see Fig. 6) . As shown in Table 11, BCGF-
FIGURE 5 . The specific binding of I25I-labeled Bb to SAC-
stimulated B cells was measured and plotted against the
amount of 125I-labeled Bb added (input) . The inset shows
Scatchard plot of this Bbbinding to SAC-stimulated B cells .
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FIGURE 6. Antibody to HMW-
BCGF recognized Bb . BCGF-
IC2, an mAb to HMW-BCGF
wasused in a Western blot anal-
ysis of HMW-BCGF (lane 1) ;
10% FCS (lane 2) ; Bb (lane 3) ;
Ba (lane 4) ; and Factor B (lane
5) . BCGF-IC2 recognized Fac-
tor B and Bb, but not Ba by
this procedure . The following
amounts ofprotein were loaded
on the gel : HMW-BCGF, 0.6
mg (10 pm); Bb, 3.61+g (60 pm);
and Ba, 2 .95 gg (84 pm).
1C2 inhibited Bb-induced proliferation of SAC-activated B cells in a dose-dependent
manner. BCGF1C2 also inhibited proliferation induced by HMWBCGF. P3X, a
control antibody, had no effect on Bb-induced proliferation when used at similar
concentrations . Thus, BCGF1C2 recognized epitopes on both Bb and HMWBCGF,
which are in proximity to sites required for their proliferative activity.
Because of the close relationship between Bb and HMW-BCGF in their effects
on B cell function, we sought to determine whether HMW-BCGF could affect com-
plement activation . However, the limited availability ofthis protein precluded direct
experiments. BCGF1C2, which inhibits HMW-BCGF and Bb activity on B cells,
did not affect C3b and Factor D-dependent Factor B cleavage or Bb-mediated C5
cleavage (data not shown) .
FIGURE 7 . (A) Polyclonal antise-
rum to FactorB recognized HMW-
BCGF A polyclonal antiserum to
Factor B was used in a Western blot
analysis ; lane 1, HMW-BCGF con-
taining supernatant ; lane 2,
purified HMW-BCGF ; lane 3, Bb ;
lane 4, Ba ; and lane 5, 5 % human
serum albumin. Identical amounts
ofprotein were loaded as in Fig. 6 .
(B) Coomassie blue stain ofBa(lane
1), Bb (lane 2), and FB (lane 3)used
in the functional and binding ex-
periments described in this paper.
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TABLE II
Bb-induced B Cell Proliferation Is Inhibited by Antibody to HMW-BCGF
Bb STIMULATES B CELL PROLIFERATION
B cells were stimulated with SAC for 48 h, washed, and then added in culture
as indicated .
Mean t SD of triplicate experiments .
Discussion
In this work we have examined the relationship between Bb, the 60-kD protease-
containing activation fragment of complement Factor B, and HMW-BCGF, a well-
described B cell growth factor (3). There is both antigenic and functional homology
between these molecules. First, antibodies made against Factor B recognize HMW-
BCGF and, conversely, antibodies made to HMWBCGF recognize both intact Factor
B and Bb. This is particularly significant in the case of the mAb BCFG-1C2, which
inhibits HMW-BCGF binding to B cells (3). Because this antibody recognizes an
epitope on BCGF1C2 at or near the cell-binding site of the molecule, we examined
whether the crossreactive antigen, Factor B, might affect B cell proliferation. We
found no effect of intact Factor B, but did find a significant enhancing effect of Bb
on B cell proliferation. The effect of Bb shared many characteristics with the known
functions of HMW-BCGF. Neither would stimulate unactivatedB cells to proliferate,
yet both could enhance proliferation of SAC- or anti-IgM-activated B cells . Both
exerted their effect primarily on large in vivo preactivated B cells . Both had no effect
on Ig secretion when added alone. These data suggest that Bb and HMW-BCGF
have functional, as well as antigenic, homology. Because Bb is serine protease, we
tested whether its proteolytic activity was required for its effect on B cell prolifera-
tion . NPGB, an irreversible serine protease inhibitor, had no effect on the ability
ofeither Bb or HMW-BCGF to induce B cell proliferation. This demonstrated that
the effect of Bb on B cells was quite distinct from its effect on monocyte spreading,
which clearly is dependent on the protease activity of Bb (21) . We do not believe
that Bb acts indirectly on B cell proliferation via stimulation of monocytes because
(a) it binds directly to SAC-stimulated B cells and an EBVtransformed B cell line ;
(b) preincubation of monocytes with Bb did not lead to enhanced B cell prolifera-
tion ; and (c) the activity of Bb on B cells was not inhibited by NPGB.
Because proteolytically inactive Bb affected B cell proliferation, we hypothesized
that its effect might be receptor mediated . Bb bound in a saturable manner to B
cells, which was consistent with a receptor-mediated event. Although the Kd for
Bb binding was rather high, the half maximal biological effect of Bb was in apoten-
tially physiologic range, perhaps suggesting that only a small percent receptor oc-
SAC plus : [ 3H]TdR incorporation
cpm
Bb, 10 pg/ml 16,221 ± 2,311'
Bb + BCGF-1C2, 0.2 Vg/ml 23,584 ± 1,567
1 .0 Vg/ml 2,758 ± 43
Bb + P3X, 1 .0 pg/ml 24,678 ± 1,190
HMW-BCGF 25% 22,352 ± 516
BCGF + BCGF-1C2, 0 .2 Vg/ml 13,968 f 2,449
1 .0 pg/ml 514 ± 22
2,693 t 387
BCGF-1C2, 1 Vg/ml 1,216 t 13
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cupancy was sufficient to transmit Bb's proliferative signal . Even more striking, HMW
BCGF inhibited the binding ofBb to B cells, suggesting that the two molecules bound
to identical or closely related sites on the plasma membrane . Taken together these
data demonstrate that Bb and HMW-BCGF have antigenic homology, including
a site known to be involved in HMW-BCGF binding to its receptor, and that Bb
and HMW-BCGF have functionally similar effects on B cell proliferation. Thus,
the ability ofBb and HMWBCGF to compete with each other for membrane binding
strongly suggests that these two molecules share a receptor expressed on activated
B cells and on the MB line .
These data raise the possibility that HMW-BCGF is, in fact, Bb . We believe that
this is not the case for the following reasons. First, HMWBCGF is synthesized by
T cells and some B cell lines, while Factor B is synthesized by monocytes. There
is no evidence for its synthesis by lymphocytes of any type. Second, pulse-chase ex-
periments have not suggested a larger molecular weight precursor forHMWBCGF
as would be expected if it were derived from Factor B (12) . Since BCGF1C2 recog-
nized intact Factor B, this precursor would have been found if it were present. Fi-
nally, although precise quantitation of the HMW-BCGF protein is difficult, esti-
mates of its potency suggest that it induces B cell proliferation at concentrations
at least 1,000-fold less than the concentrations of Bb required to induce B cell prolifer-
ation . Thus, although there is homology in the cell-binding epitopes ofBb and HMW-
BCGF, these are clearly distinct molecules .
The data presented here lead us to hypothesize a new mechanism by which pep-
tides produced at sites of inflammation or infection can affect immune function .
Since HMW-BCGF alone does not induce differentiation ofB cells into plasma cells,
its primary role in vivo is likely to be to provide a signal for the clonal expansion
of antigen-stimulated B cells . Ourwork suggests that Bb can have a physiologic role
similar or identical to HMW-BCGF. Assuming that the concentration of Factor B
present at a site of inflammation is approximately equal to serum (2.5 PM), cleavage
of only 1-5% of Factor B would achieve concentrations of Bb capable of significant
stimulation of the growth of antigen-activated B cells . Thus, Bb could be a signal
for the proliferation ofantigen-activated B cells, which is generated early in the inflam-
matory process. HMW-BCGF, which is synthesized by activated T cells, would not
be present until later times after the inflammatory event, and could serve to sustain
the clonal expansion of antigen-activated B cells . Other complement components,
lymphokines, and inflammatory molecules will also act to regulate B cell function
at sites of inflammation . The net effect on B cell physiology would be the sum of
a very complex set of stimuli . Nonetheless, this receptor-mediated, nonprotease effect
of Bb suggests a mechanism through which complement activation, as part of a
nonspecific response to antigenic challenge, can provide an early signal to enhance
the antigen-specific immune response.
Summary
The process of B cell growth and differentiation into plasma cells is highly regu-
lated and maybe influenced by a large number of inflammatory mediators, including
complement components . We have studied the regulatory influence of Bb, a 60-kD
peptide created during the cleavage of complement Factor B by Factor D and C3b.
Purified Bb alone had no effect on proliferation and differentiation ofhuman splenic
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or tonsillar B cells . However, when B cells were activated by Staphylococcus aureus Cowan
I (SAC), Bb enhanced proliferation in a dose-dependent manner. Bb also enhanced
proliferation when cocultured with SAC and suboptimal concentrations of purified
60-kD B cell growth factor (HMW-BCGF), a previously described lymphokine that
is known to possess growth-promoting activity. However, Bb had no effect on cells
treated with optimal concentrations of HMW-BCGF Like HMW-BCGF, Bb's major
effect was on the larger in vivo activated B cells . Half-maximal enhancement of prolifer-
ation was reached at a Bb concentration of 1-10 nM. Ofnote is the fact that antibody
to Factor B recognized HMW-BCGF, and an mAb to HMW-BCGF also recognized
Factor B and Bb, but not Ba . Moreover, radiolabeled Bb bound saturably to acti-
vated B cells and to an EBVtransformed human B cell line . The binding of Bb was
inhibited by HMW-BCGF but not by Ba or IgG. Thus, Bb is antigenically and func-
tionally related to HMW-BCGF, and can act as a B cell growth and differentiation
factor at potentially physiologic concentrations . These data suggest that Bb may be
important in amplifying the immune response in areas of inflammation . Since com-
plement activation occurs at inflammatory sites long before induction of HMW-
BCGF synthesis, Bb may be an early signal for the clonal expansion of antigen-
activated B cells .
The authors thank Ms. Joyce Rudolph for excellent secretarial assistance and Patrick
McFarland, Howard Mostowski, Norma Witzel, and Alex Zheleznyak for technical assisitance .
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